2012 annual report in pdf - Leiden Bio Science Park

New sports fieldsPhoto by Pascale NeuteboomEconomic developmenT of the parkNew arrivalsLeiden Bio Science Park welcomed 18 newcompanies in 2012. These companies comefrom other parts of the Netherlands, arenew start-ups from Leiden University orLeiden University Medical Center and aUS and a Japanese company opened theirEuropean headquarters in Leiden. The newcluster members in 2012 were:· Applied Radar Technology· Astellas· ASTP· Avedas· Buchem· DCPrime· EnVivo· H a l i x· Hilton Garden Inn· i M D s o f t· In Ovo· Level· Lexis Nexis Univentio· Life Science Methods· Mimetas· OcellO· Pluriomics· ProQR Therapeutics6

Ground breaking ceremony Avery DennisonPhoto by Henk de GraafTop CHDR building reachedPhoto by Jeroen HiemstraUnder constructionAvery Dennison officially started theconstruction of their new lab-officebuilding with a ground breaking ceremonyat the Oegstgeest area of Leiden BioScience Park. They expect to open thefacility in the summer of 2014.The new hotel Hilton Garden Inn welcomedits first guest in August 2012.The construction of BioPartner CenterLeiden building 2 has been completedand in December the first tenant, to-BBB,moved in. The rest of the tenants willfollow in the first quarter of 2013. The newbuilding of CHDR reached its top in 2012and is also expected to be opened in thefirst quarter of 2013.The board of the Leiden Bio Science Parkfoundation (LBSPf) decided to build the BioSimulation Factory. The construction willstart in 2013 and the opening is plannedin 2015. The new sporting fields of theUniversity were opened in December 2012.The fields include a tennis, hockey and asoccer/rugby field and a running track.

Astellas openingPhoto by Jet Heyse8

Marketing & communicationAcquisitionWorking closely together with and makinguse of the services offered by both theNetherlands Foreign Investment Agency(NFIA) and WestHolland Investment Agency(WFIA), Leiden Bio Science Park aims toattract new (inter)national companies tothe park. 2012 Was a successful year. Over33 companies showed interest in Leiden BioScience Park for a new or extra location,resulting in 11 official Fact Finding tripsto the park and the establishment of 18new companies in Leiden Bio Science Park.Another 20 delegations visited the park.Also in 2012 Leiden Bio Science Parkactively networked, lobbied and intensifiedrelations throughout internationalconventions in Amsterdam, Boston,Hamburg and Taiwan. Road shows wereheld at the west coast of the USA and inJapan to get in contact with companiesinterested to establish in Leiden and/orto set up collaborations with companiesat the park. During the side event thatwas organised supplementary to the BioAmsterdam convention, 18 representativesvisited the park.NetworkingLeiden Bio Science Park hosted visits fromnational and local politicians and policymakers from the Ministry of EconomicAffairs, the economic department of theProvince of South Holland and the City ofLeiden.Diederik Samsom at HAL AllergyPhoto by Hermine Klein10

Diederik Samsom, leader of the Dutch socialdemocratic party PvdA, visited the HalAllergy production facility where vaccinesagainst allergies are made and Marco deBoer and Werner Gladdines explainedhow to-BBB developed from a universityspinout into a promising company with adrug delivery platform and clinical researchin brain diseases. Roelof van Laar, citycouncillor of PvdA Leiden, visited 10 LeidenBio Science Park companies to meet withtheir CEOs.The average number of participants of themonthly Life Sciences Café networkingevent of the park increased to around 70.Together with the entrepreneurial societyof Leiden Bio Science Park (OV BSP), regularCEO breakfast meetings were organizedin 2012. The breakfasts are well attendednetworking events where current issues canbe discussed in an informal setting. Also,a new initiative popped up in 2012; themonthly Science meets Business meetingsfor young entrepreneurs.In 2012 the park was home to manyconferences, for example the annual DutchLife Science & Health conference which washeld in CORPUS. The event, an initiative ofIventus, attracted around 280 participantsworking on business development in lifesciences and was supported amongst othersby the cities of Leiden and Oegstgeest.On November 5, a BV Leiden meeting washeld at the BioPartner Center which wasattended by around 115 entrepreneurs fromin and around Leiden.On Sunday October 28, Leiden BioScience Park companies Aeon Astron andBabybloom participated in the annualScience Day in Leiden with lectures on theirresearch on eye diseases and the ergonomicbaby incubator.Well connectedLeiden Bio Science Park is an activeparticipant in the formation of MedicalDelta, the consortium of academia, industryand government in the Delft, Leiden andRotterdam area, where new innovationsare developed at the edge of clinical andengineering sciences.Through Medical Delta, Leiden Bio SciencePark also contributes to HealthTIES,a European ‘Regions of Knowledge’project aimed at developing a ‘virtualreference region’ for innovation in lifesciences. Leiden Bio Science Park is alsomember of the Steering Committee ofthe Council of European BiotechnologyRegions, an initiative aimed at intensifyingcollaboration between biotech scienceparks throughout Europe.11

Leiden BioScience4035Phase in pipelineParkpipeline30252015102009201020112012Preclinical 16 31 28 33Phase I 14 19 16 20Phase II 22 24 29 28Phase III 3 3 3 5Pending approval 4 5 3 2Market 30 40 35 30n products50PreclinicalPhase IPhase IIPhase IIIPending approvalMarketDiseaseclassificationat Leiden BSPn productsDisease classification858075702520151050AutoimmuneBlood & lymphatic diseasesCancerCVSCNSDermatologyDigestive systemGenetic disordersInfectionsKidneys and genito urinary systemMetabolic/endocrinologyMusculo-skeletal disordersRespiratory systemWomens HealthMiscellaneous2009201020112012Autoimmune 10 11 11 17Blood & lymphatic diseases 6 4 7 9Cancer 9 9 15 20CVS (cardiovascular and 1 1 2 1circulatory system)CNS (central nervous system) 6 7 8 22Dermatology 5 5 5 4Digestive system 3 3 4 2Genetic disorders 2 2 2 3Infections 70 72 77 81Kidneys and genito 2 1 0 0urinary systemMetabolic/endocrinology 6 7 6 5Musculo-skeletal disorders 10 18 17 17Respiratory system 4 3 3 3Womens Health 1 1 2 3Miscellaneous 3 0 1 1Development phaseDevelopmentphase LeidenBSP companiesn companies50403020100Research &discoveryProduct & processdevelopmentClinical trialsManufacturingDistribution &sales2009201020112012Research & discovery 28 31 32 39Product & process 23 26 27 34developmentClinical trials 16 18 19 21Manufacturing 13 14 17 23Distribution & sales 13 14 19 24

DEVELOPMENT OF COMPANIESAT LEIDEN BIO SCIENCE PARKLeiden Bio Science Park pipeline anddisease classificationThe pipeline of drug developing companiesat Leiden Bio Science Park continues to showmore new compounds into Phase I trialsand the further development of productsfrom Phase II to Phase III trials in 2012. Forexample, ProFibrix started Phase III clinicaltrials with Fibrocaps.In 2012 the disease classification showsthat the area most researched in Leiden,infectious diseases, continued to increase.Crucell, Galapagos, Mymetics, OctoPlusand to-BBB are active in clinical trials inthis area. Product development in the fieldof the central nervous system by newlyestablished EnVivo, Galapagos, Prosensaand to-BBB grew fast, compared to 2011the number of trials in CNS nearly tripled.Other large research areas that continuedto grow are auto-immune diseases (researchby Galapagos, Hal Allergy, Janssen Biologicsand Pharming), blood & lymphatic diseases(ProFibrix) and cancer (new companyDCPrime, ISA Pharmaceuticals, Galapagosand to-BBB).Facts and figuresIn total about 15,500 people were employedat Leiden Bio Science Park in 2011*.There are 154 organisations at Leiden BioScience Park of which 117 companies, 12research institutes, 7 educational institutes,9 care related organisations and 9 otherorganisations. 88 Of the 117 companies arededicated to life sciences, 8 work in IT, 9 inother academic areas and 12 companiesare active in other areas.Again more companies establishedthem selves at the park than in previousyears. In 2012, 18 new organisations cameto the park, compared to 16 in 2011, 10in 2010 and 7 in 2009. 12 Of these 18 newcompanies are service providers.Due to the growth in the number ofcompanies, the last table does not onlyshow an increase of all phases in the valuechain but moreover emphasizes the furtherdevelopment of the park.* Latest available employment figures are of 2011,all other figures are of 2012.13

Made in LeidenResearch newsResearchers from Crucell and The ScrippsResearch Institute identified the first humanmonoclonal antibodies that appear capableof disabling all influenza B viruses. Thediscovery, published in the journal Science,addresses a significant missing link in thedevelopment of universal therapies and ageneral vaccine for flu.Galapagos’ most advanced candidatedrug, GLPG0634 for the treatment ofrheumatoid arthritis (RA) and potentiallyother inflam matory diseases, showedimprovement in the signs and symptoms ofRA and a unique safety profile in two PhaseII studies. Galapagos started its secondPhase I clinical study with GLPG0974, aGPR43 inhibitor being developed to treatchronic inflammatory bowel disease. Inidentifying the first pre-clini cal candidatecompound, Galapagos delivered acandidate drug in osteoarthritis in alliancewith Servier. Galapagos also disco vered anentirely new class of anti biotics, a candidatedrug that shows strong activity against alltested drug resistant Staphylococcus aureus,including hospital and community acquiredMRSA strains.HAL Allergy completed patient enrollmentin several studies: a Phase II study withPURETHAL ® Mites in patients with persistentallergic rhinitis/rhinoconjunctivitis, a PhaseII trial with SUBLIVAC ® FIX Birch and a PhaseII trial with SUBLIVAC ® FIX Phleum pratense.Leiden University Medical Center (LUMC)is the first in Europe to use a CE approvedcamera system that uses fluorescence tovisualize tumours in cancer patients duringsurgery.Naturalis Biodiversity Center succeededto photograph and digitise one millioninsects in just over a year. The CollectionDigitisation of Naturalis - one of the largestdigitisation projects of natural historycollections in the world - will compriseseven million objects in 2015.Pharming started a paediatric Phase IIclinical study with Ruconest, completeda Phase III clinical study in North Americaand new data were published onRuconest’s protective effects after severeblood loss. Pharming confirmed the safetyprofile of recombinant human Lactoferrinin a food safety study in healthy humanvolunteers.ProFibrix started enrolling patients in itspivotal Phase III clinical trial with Fibrocaps(FINISH-3).14

Prosensa selected clinical candidates fortwo more compounds for the treatment ofDuchenne muscular dystrophy (DMD) andhas been granted orphan drug designationfor these two additional DMD compounds.The universities and medical centres ofLeiden, Delft and Rotterdam joined forces inVITALITY, a research programme that aimsto improve the resilience, productivity andquality of life of the elderly.Number of products in the pipeline per disease area of Leiden Bio Science Park companies in 2011 and 201250454035302520 1611102011 2012MarketPending approvalPhase IIIPhase IIPhase I20151111128Preclinical1050833Autoimmune and inflammation613 11343Blood and lymphatic system1521 15 112122 31 12744 4 2 215 52 1 1 1 1 1 1 1 112 2 2 2CancerCardiovascular and circulatory systemCentral nervous systemDermatologyDigestive systemGenetic diseases and dysmorphic syndromes7InfectionsMetabolic/endocrinologyMusculo-skeletal disordersOphthalmology and optometryRespiratory and pulmonary systemWomens health1Miscellaneous15

Business NEWS in 2012Aeon Astron Europe received a governmentgrant of up to € 0.5 million for its BioLensproject and was awarded the first InnovationCredit under the regulations of the new topsector policy to develop an artificial cornea.With partner Life Technologies, BAClaunched high speed affinity HPLC columnsfor real-time pharmaceutical processmonitoring and they collaborate with GEHealthcare to launch a new bioprocessaffinity resin.BaseClear and Naturalis Biodiversity Centeragreed on a DNA sequencing deal. Duringthe next two years, BaseClear will performall routine DNA sequencing associated withthe 'DNA Bar coding' project.Dutch Space signed a contract of over € 13million for the delivery of a second series ofGalileo solar arrays. Dutch Space deliveredthe Embedded Training System for the F-35Lightning II Joint Strike Fighter to LockheedMartin.EnVivo announced statistically significantand clinically meaningful results of theirsix-month, double-blind Phase IIb clinicaltrial evaluating EVP-6124 against placebo inpatients with mild to moderate Alzheimer’sdisease.In a collaborative effort, FlexGen, LeidenUniversity Medical Center and BGI willvalidate a set of variants in a large setof trio samples from the Genome of theNetherlands (GoNL) project.GlaxoSmithKline will exclusively license thecompounds GLPG0778 and GLPG0555 withinthe immuno-inflammatory alliance withGalapagos. February 29 Galapagos signed aglobal agreement with AbbVie to developand commercialise GLPG0634. Galapagosreceived € 3.5 million after achievingmilestones in its osteoarthritis alliancewith Servier and a milestone payment of€ 6.6 million in its alliance with JanssenPharmaceutica.HAL Allergy extended its GMP contractmanufacturing activities for clinical batchsupply of both recombinant and viralproducts under the spin-off company Halix.Researchers from the Leiden AcademicCentre for Drug Research (LACDR) received16

Ruud SantingCEO Sinensis Life Sciences“With the acquisition of MicroSafe Laboratories from Merck-Millipore ownership returned toLeiden Bio Science Park. MicroSafe was founded in 1993 and became renowned for its highquality mycoplasma testing capacities. Recently three other Dutch laboratories (Farmalyse inZaandam, Bactimm in Nijmegen and Prolepha in Etten-Leur) joined forces under the umbrellaof our new holding company Sinensis Life Sciences. Sinensis is also located on Leiden Bio SciencePark and will expand its services portfolio to support the life sciences industry.”€ 0.2 million from STW to further developtheir work on Organs on-a-Chip. Theirspin-off company Mimetas will bringsolutions for micro tissue and organculturing to the market.OctoPlus announced that Dr. Reddy'sLaboratories intends to make arecommended public offer for OctoPlus.Pharming concluded several distributionagreements for Ruconest in South-East Asia.Pharming closed its US based cattle platformresearch operations and sold its US facilities.It will focus on its transgenic rabbit platformand announced a strategic restructuringplan of its Dutch operations. Pharming alsosecured a € 10 million working capital facilityand received a US$ 10 million milestonepayment under the license agreement withSantarus as a result of the successful Phase IIIclinical study of Ruconest.Prosensa raised € 23 million in new equityfinancing.A traditional Chinese herbal medicine hasbeen licensed by SU BioMedicine for salein the Netherlands, making it the first TCMdrug to receive marketing authorization in aWestern market.Taiwan Liposome Co, TLC, made animpressive trading debut in Taiwan. Stocksrose nearly 76% on its trading debut onthe GreTai Securities Market after raisingNT$ 729.96 million (US$ 25.07 million) inits initial public offering.TNO and CHDR joined forces in clinicalresearch and form a new partnership forfood related clinical trials.to-BBB received funding by The MichaelJ. Fox Foundation and an InnovationCredit from the Dutch government toconduct preclinical research targetingneuroinflammation in Parkinson’s diseasewith its product 2B3-201. to-BBB wasawarded € 1.25 million by the EU’s 7 thFramework Programme to developtreatments for inherited retinal diseases.17

CompanyhighlightsBAC and their long-term collaboration withGE Healthcare has been recognized withthe “Collaboration of the Decade Award –Downstream Processing” at the BioProcessInternational Awards 2012.As of February 2012 Batavia Bioservices alsodeploys dedicated BSL-2 laboratories in theGreater Boston area.On April 26 the iconic new building ofCentre for Human Drug Research reachedits highest point. CHDR and Good BiomarkerSciences, partner of CHDR since long time,will move into the new building in thebeginning of 2013.EnVivo Pharmaceuticals located its Europeanoffice in Leiden. The choice for LeidenBio Science Park further underscores theinternational reputation of the Life Sciencescluster in Leiden.Wouter Bruins and Wil Stutterheim of In Ovo, the EggspertsPhoto by Hans Lebbe18

Adam CohenCEO Centre for Human Drug Research“Leiden Bio Science Park has been our home for the past 20 years. When we decided to build anew clinical research unit the decision to stay close to our previous spot was easily taken. Superbpossibilities for scientific and operational collaboration, excellent applicants for any job we have onoffer and all amenities including Schiphol airport within easy reach were some of the considerationsfor us and our customers. The help we received from Leiden in realising our new landmark in LeidenBio Science Park was an example of the entrepreneurial spirit in our city council.”Galapagos won the European MediscienceAwards for Transaction of the year and ChiefExecutive of the year.In November the young Leiden biotechcompany In Ovo (the Eggsperts) won theencouragement prize for their innovative,humane and sustainable solution to thepoultry industry at the Herman WijffelsInnovation Prize ceremony.In February NCB Naturalis startedpreparations for the construction of the newbuilding adjacent to the existing museum.On July 12, NCB Naturalis changed its nameinto Naturalis Biodiversity Center as aconsequence of the merger of Naturalis,the Zoological Museum Amsterdam and theNational Herbarium.ProQR Therapeutics strengthened itsadvisory board with the appointment ofHenri Termeer as a strategic advisor andinvestor.In 2012 Prosensa won the “Emerging StarAward” at the European MediscienceAwards and has been named one of 2012’sFierce 15 by FierceBiotech, designatingit as one of the most promising privatebiotechnology companies in the industry. InDecember Henri Termeer was also appointedas strategic advisor at Prosensa.In March PROXY Laboratories acquiredMicroSafe Services from Merck Millipore,the Life Science division of Merck KGaA,Germany.On May 1 the first teams of the mentalhealth organisation Rivierduinen, GGZLeiden and a part of GGZ Children andYouth, moved into the new Rijnvestebuilding in Leiden.to-BBB was awarded the 2012 EuropeanCNS Targeted Drug Delivery TechnologyInnovation Award by Frost & Sullivan,recognizing to-BBB for delivering excellenceand best practices in this challenging field.19

Henk Venemamanager BioPartner Center Leiden“After the success of the Accelerator, in 2011 the board and advisory board decided to build a twinbuilding to replace the BioPartner building at the Niels Bohrweg. In December 2012 the first tenant,to-BBB, moved into the new building. BioPartner Center Leiden has now 3 buildings in a campussetting, located next to each other with in total around 10.000m² office and lab space available forstarters and maturing young companies.”Expat meeting at SligroPhoto by Expat Centre LeidenBioPartner2 buildingPhoto by Paul Voshol21

Photo left: Minister Jet Bussemakerawards LiS with Centre for InnovativeCraftsmanshipPhoto by Platform Bèta TechniekLURIS, the technology transfer officeof both LUMC and Leiden University,successfully helped academics to bring theirinventions on the market. 17 Technologieswere commercially licensed out, 11technologies are under evaluation for alicense for either an existing company ora spin-off company and 18 new patentswere filed.EducationThree educational centres in Leidenreceived significant contributions for theirplans to link education, training and workin life sciences and health. More than€ 15 million of contributions were madeby organisations such as the Platform BètaTechniek, the European Fund for RegionalDevelopment, the city of Leiden, industryand many more.· The Hogeschool Leiden was awardeda Centre of Excellence for Genomics,which will accelerate the application ofgenomics sequencing in various domains,together with many other parties in andaround the park.· The Leiden instrumentmakers Schoolwill develop a Centre for InnovativeCraftsmanship in the area of precisiontechnology for life sciences, again withmany other parties.· Leiden Bio Science Park will build the BioSimulation Factory, a training hub forGood Manufacturing Practice, targetedat customers from within and beyondthe park.In collaboration with LUMC and Iventusthe first conference targeted at researchtechnicians was organised which provedto be a great success and will be continuedby Iventus.Labour flex poolsThe flexible, regional labour poolof experienced biopharmaceuticalprofessionals BioScience@work (part ofRandstad Techniek) fulfills the increasingneed of employers to create flexibility byinterchanging employees during periods inwhich the demand for employees stronglyfluctuates. By the end of 2012, 24 peoplehave started working for BioScience@workand the first successful interchangesbetween companies took place.BirdBioflex, a flex pool initiative of theOV BSP for the temporary exchange ofpersonnel between companies on thebio science park, became operationaland the first exchange took place in 2012.23

People involved in the developmentof Leiden Bio Science Park IN 2012Board of the Leiden Bio Science Park foundationWillem te Beest, chairman, vice president executive board LeidenUniversityFerry Breedveld, vice chairman, chairman LUMCRobert Strijk, treasurer from July 2012, alderman city of LeidenPedro Tetteroo, (thru June 2012) treasurer, coachErna Barèl, chairman entrepreneurial society OV BSP, co-founderof BaseClearMenzo Havenga, CEO Batavia BioservicesToon Stegmann, CSO MymeticsAdvisory BoardDouwe Breimer, former president Leiden UniversitySander van Deventer, general partner Forbion Capital PartnersHarry Flore, CEO HAL AllergyJeff Gielen, director Kadans BiofacilitiesDick Harms, director Leiden instrumentmakers SchoolRené de Jong, managing director Rabobank Leiden, Leiderdorp andOegstgeestAnne Willem Kist, former president Leiden UniversityJeroen Knigge, chairman executive board ROC LeidenRoelof Konterman, chairman Achmea ZorgAda Kruisbeek, founder DCPrimeHenri Lenferink, mayor city of LeidenPaul van Maanen, chairman executive board Hogeschool LeidenMaarten van der Plas, policy advisor city of LeidenBas Reichert, co-founder and operational director BaseClearHenri Remmers, founder Corpus ExperienceRuud Santing, CEO Sinensis Life SciencesHans Schikan, CEO Prosensa TherapeuticsBob Smailes, managing director LURISRuud van Spronsen, real estate developer PCS DesignRein Strijker, CEO VitalneXtPedro Tetteroo, coachEls Timmers, mayor city of OegstgeestDinko Valerio, founder Crucell, general partner Aescap VentureGovert Veldhuijzen, deputy Economic Affairs province of SouthHolland24

In June of 2012 we received the sad news of thedeath of professor Rob Schilperoort. In theEighties he was one of the key players in settingup Leiden Bio Science Park. We are very gratefulfor his huge efforts in this area.Rob SchilperoortPhoto by the Schilperoort familySjoerd Verduyn Lunel, (thru August 2012) dean Science facultyLeiden UniversityWillem van Weperen, CEO to-BBBRein Willems, member of the senate for CDAOfficeNettie Buitelaar, managing directorHermine Klein, marketing managerCarla van der Laan, office manager, HR consultantLeon Mur, (thru January 2012) project manager labor marketMiranda de Regt, office manager (thru January 2012)Ellen Smit, account manager and business park manager OV BSPSupport networkMark Bottema, province of South HollandJessica Hilhorst, city of LeidenHans Goossensen, province of South HollandRoel Meeuwesse, ministry of Economic AffairsMaarten van der Plas, city of LeidenRonald Stokkel, city of LeidenDealflow meetingsLissa Boxy and Wim Rutgers, WFIAAnnelies den Breejen, Chamber of CommerceCurt Daniel, LURIS (thru July 2012)Frans Dekker, Leiden University, real estateLoes van Groningen, LUMC, real estateLaura MacDonald, LURIS (from August 2012)Maarten van der Plas and Jessica Hilhorst, city of LeidenLaura Platte, city of OegstgeestEllen Smit, Leiden Bio Science Park foundationHenk Venema, BioPartner Center Leiden25

3D-One ActiveView Connect Groep Add2X Biosciences Aeon Astron Europe AmarnaTechnology ASTP Astellas Pharma Europe AVEDAS Babybloom Healthcare BACBioScience@work BiosparQ BioTop Medical Bird Recruitment BISLIFE foundationHuman Drug Research Chiltern International ChiralVision Circle Cardiovascular ImagiCulgi CuraRata CWTS Darwin Digits DCPrime De Stal Delta Crystallon DeltaCeTrials & Study Office EnVivo Pharmaceuticals ETI BioInformatics ExPlant TechnologiGiMaRIS Giotto Management Consultants Good Biomarker Sciences HAL Allergy HaliIEMO iMDsoft In Ovo ISA Pharmaceuticals Janssen Biologics Kenniscentrum LeidProbe Microscopy Leiden Bio Science Park foundation Leiden the Leiden University Bio Science Park Leiden Univeinstrumentmakers School LeveDNA! Level LexisNexis Univentio Leyden Academy on VitMediLingua Medis Medical Imaging Systems Membrane Protein Laboratory Mentor MMimetas Mymetics Nalco Naturalis Biodiversity Center NBIC Netherlands BioinfPharming Phila del Art Pluriomics ProFibrix Promasys Promega ProQR TherapeProxy Laboratories Questions Answers and More Rijnlands Revalidatiecentrum ROCContacten Bedrijfsleven Stichting Interplast Holland Stichting Opsporing Erfelijke TBBB technologies Toko Top Institute Pharma TOPLab Hogeschool Leiden TrombosedieVWR Wilkens C.S. Medical Translations Willem Alexander Kinderfonds Xendo ZF-pharColofonThis report is published byfoundation.DesignRatio Design, HaarlemPrintDrukkerij Brummelkamp,Hoofddorp

Therapeutics Apexmed International Apotex Applied Microspheres Applied RadarBaseClear Batavia Bioservices Berckheijde BioClinica BioPartner Center LeidenBuchem CAM Bioceramics Catexel Cell Signaling Technology Europe Centre forng Clinical Reach Drug Development Compaan Design CORPUS Cosine Crucell CSCll Derphartox Dianova DuPont Industrial Biosciences Dutch Space EBMT Clinicales Falco Biotherapeutics FlexGen Fytagoras Galapagos GGZ Leiden - Rivierduinenx helpLine Hilton Garden Inn Hogeschool Leiden Hoogheemraadschap van Rijnlanden Labolutions LAP&P Leiden Academic Centre for Drug Research (LACDR) Leidenrsity Medical Center Leiden University Research & Innovation Services (LURIS) Leidseality and Ageing Life Science Methods LifeScienceGo Link LSJ Medisch Projectbureauedical Systems MEVS MicroSafe Laboratories Millford Brand-id Miltenyi Biotecormatics Centre NeCEN NewCatch Nijssen Koeling OcellO OctoPlus OV BSPutics Prosensa Therapeutics Protein Labelling Innovation Technologies ProteoNicLeiden Sanquin blood bank ServiceXS Servier SOFC STI Management Stichtingumoren (StOET) Stichting Valk Syntecnos Szienz TLC BioPharmaceuticals TNO tonstLeiden Verilabs Nederland Verloskundig Centrum De Poort VisiMetrix VitalneXtma ZF-screens Zijlstra Verpakapotheek Zirkzee Group ZoBio Zorg Academie Leiden

www.leidenbiosciencepark.nlLeiden Bio Science Park foundation · Rijnsburgerweg 10 · Poortgebouw Noord · 2333 AA Leiden · The Netherlands · T +31 (0) 71 524 75 55